

## UNITED STAT DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/268,892	03/16/99	HARTFIELD	G	D-43025-01
		$\neg$	EXAMINER	
		MM91/1011		
CRYOVAC INC			NGHYEN_K	
0 BOX 464			ART UN	IIT PAPER NUMBER
DUNCAN SC 29334				
			2881	
			DATE MAIL	ED:
				10/11/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

	Application No.		Applicant(s)	
Office Action Summary	04/268,892		HARTFIELD.	
Omec Action Summary	Examiner	•		Group Art Unit
	L. K. M	<u></u>		2881
—The MAILING DATE of this communication appears	on the cover s	heet be	neath the co	rrespondence address
ri df r Reply				
SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO F THIS COMMUNICATION.	EXPIRE	3	_MONTH(S)	FROM THE MAILING DAT
<ul> <li>Extensions of time may be available under the provisions of 37 CFR 1.1 from the mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days, a replete.</li> <li>If NO period for reply is specified above, such period shall, by default, efficiency to reply within the set or extended period for reply will, by statute.</li> </ul>	y_within the statutor	y minimu 'HS fmm	m of thirty (30) o	ays will be considered timely.
tatus/	,			
Responsive to communication(s) filed on	-20-01			
☑ This action is FINAL.				•
☐ Since this application is in condition for allowance except for accordance with the practice under Ex parte Quayle, 1935	or formal matters C.D. 1 1; 453 O.	, <b>prose</b> G. 213.	cution as to t	he merits is closed in
isposition of Claims	•			
V Claim(s) 1-10, 13-15 and 17-	-37		10/050 0	andina in the court of
Of the above claim(s)	is/are pe	ending in the application.		
Claim(s)				
M Claim(s) 1-10, 13-15 and 17-3	7		is/are all	owed.
G Claim(c)			is/are re	ected.
☐ Claim(s)			is/are ob	jected to.
□ Claim(s)————————————————————————————————————		<u> </u>	are subje requirem	ect to restriction or election ent.
☐ See the attached Notice of Draftsperson's Patent Drawing R	Navidania BED 040			
☐ The proposed drawing correction, filed on	ieview, PTO-948		41	
	is □ appro to by the Exami	veu 📋	alsapproved.	
☐ The drawing(s) filed on is/are objected	to by the Examp	iici.		
<ul><li>☐ The drawing(s) filed on is/are objected</li><li>☐ The specification is objected to by the Examiner.</li></ul>				
☐ The specification is objected to by the Examiner.				
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> </ul>	r 35 U.S.C. § 11 priority docume	9(a)-(d) nts have	been	
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>i rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under □ All □ Some* □ None of the CERTIFIED copies of the □ received.</li> <li>□ received in Application No. (Series Code/Serial Number)_</li> </ul>	priority docume	nts have	been	
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>i rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under a large of the CERTIFIED copies of the large received.</li> <li>□ received in Application No. (Series Code/Serial Number) received in this national stage application from the International stage application from the International stage application.</li> </ul>	priority docume	CT Rule	been	· ·
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>i rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under</li> <li>□ All □ Some* □ None of the CERTIFIED copies of the</li> <li>□ received.</li> <li>□ received in Application No. (Series Code/Serial Number)_</li> <li>□ received in this national stage application from the Internal</li> <li>*Certified copies not received:</li> </ul>	priority docume	CT Rule	been	· ·
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>i rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under a claim for foreign priority unde</li></ul>	priority document	CT Rule	been	
☐ The specification is objected to by the Examiner.  ☐ The oath or declaration is objected to by the Examiner.  i rity under 35 U.S.C. § 119 (a)-(d)  ☐ Acknowledgment is made of a claim for foreign priority under ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the ☐ received. ☐ received in Application No. (Series Code/Serial Number)_☐ received in this national stage application from the International copies not received:	priority document	CT Rule	been 1 7.2(a)). vi w Summa	
<ul> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>i rity under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority under a large of the CERTIFIED copies of the large received.</li> <li>□ received in Application No. (Series Code/Serial Number) received in this national stage application from the International stage application from the International stage application.</li> </ul>	priority document	CT Rule	e 1 7.2(a)).  vi w Summan	y, PTO-413 Patent Application, PTO-15

Part of Paper No. \_\_

## Rejection Under 35 U.S.C. 112, Second Paragraph

Claim 37 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim-37-recites-the-limitation "the one or more dosimetric agents" in line 2. There is insufficient antecedent basis for this limitation in the claim.

## Rejection Under 35 U.S.C. 102(b)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2, 4-8, 10, 13-15, 17-23, 26 and 36 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Regulla et al. (Dosimetry by ESR spectroscopy of Alanine).

Claims 1-5, 7-10, 13-15, 17-23, 27, 29-30, 32 and 35-37 are rejected under 35 U.S.C. 102(b) as being anticipated by Morita et al. (See the reasons as indicated in the previous office action dated April 16, 2001 in Paper No. 7).

## Rejection Under 35 U.S.C. 103(a)

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 6, 24-26, 28, 31 and 33-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morita et al.

Morita et al. disclose all the features, as discussed in the previous office action dated April 16, 2001 in Paper No. 7, except a food product or a beverage product as recited in claims 6 and 26; a sugar as recited in claim 24; an amine salt of an organic acid as recited in claim 25; ethylene/C<sub>3</sub>-C<sub>20</sub> alpha-olefin copolymer as recited in claim 28; ethylene/C<sub>1</sub>-C<sub>20</sub> ester of (meth)acrylic acid copolymer as recited in claim 31; polyamide as recited in claim 33; and ionomer as recited in claim 34.

Using the authenticating agent such as the sugar or the amine salt of an organic acid in the food product or the beverage product is considered to be obvious variation in design, since it well known in the art to use such agents in the food or beverage product for testing the product, thus would have been obvious to one skilled in the art to use the authenticating agent such as the sugar or the amine salt of an organic acid in the food product or the beverage product in the Morita et al. dosimeter for testing the product.

Using the material such as the ethylene/ $C_3$ - $C_{20}$  alpha-olefin copolymer, the ethylene/ $C_1$ - $C_{20}$ ester of (meth)acrylic acid copolymer, the polyamide or the ionomer for packaging the authenticating agent is also considered to be obvious variation in design, since it well known in the art to use the material such as the ethylene/C<sub>3</sub>-C<sub>20</sub> alpha-olefin copolymer, the ethylene/C<sub>1</sub>-C<sub>20</sub>

ester of (meth)acrylic acid copolymer, the polyamide or the ionomer in the Morita et al. dosimeter for packaging the authenticating agent.

Applicant's arguments filed on August 20, 2001 have been fully considered but they are not persuasive.

Applicant-argued that both Regulla et al. and Morita et al. fail to disclose a package for containing an authenticating agent.

This argument is not persuasive. Regulla et al. disclose the amino acids or alanine which are packed in the form of the sample units (see fig. 15); and Morita et al. disclose the molded product contains alanine (see col. 3, line 55) and the rubber and alanine which are filmed to form a sheet (see col. 4, lines 1-3 and 45-48). Further, the alanine is the powder; therefore it is needed to form an unit for a test piece. Since the term "the package" is generally defined as an unit for containing elements.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 2881 Paper No. 11

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner *Kiet T. Nguyen* whose telephone number is (703) 308-4855.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0956.

Papers related to Art Unit 2881 applications only may be submitted to Art Unit 2881 by facsimile transmission. Any transmission not to be considered an official response must be clearly marked "DRAFT". The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Art Unit 2881 Fax Center number is (703) 308-7723.

K.T.N/Primary
October 10, 2001

KIET T. NGUYEN PRIMARY EXAMINER